Xeris Biopharma Holdings Inc. has outlined a strategic roadmap aimed at achieving long-term growth and value creation. The company plans to leverage its financial strength for self-funding both near- and long-term growth, driven by rapid revenue growth and disciplined capital management. A key component of this strategy is the anticipated revenue acceleration of Recorlev®, which is expected to mark a pivotal growth phase. Xeris has set a 2025 revenue target between $260 million and $275 million, with intentions to remain adjusted EBITDA positive. Looking further ahead, the company projects total revenue to reach approximately $750 million by 2030, led by Recorlev®. By 2035, Recorlev® is anticipated to achieve annual net revenue of approximately $1 billion, while XP-8121 is expected to reach peak net revenue of $1 to $3 billion. These projections are part of Xeris's commitment to delivering innovative solutions and addressing unmet medical needs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.